{"id":451266,"date":"2021-03-04T16:08:32","date_gmt":"2021-03-04T21:08:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451266"},"modified":"2021-03-04T16:08:32","modified_gmt":"2021-03-04T21:08:32","slug":"siga-reports-financial-results-for-three-and-twelve-months-ended-december-31-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/siga-reports-financial-results-for-three-and-twelve-months-ended-december-31-2020\/","title":{"rendered":"SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020"},"content":{"rendered":"
\n

\n – <\/strong>
\n \u00a0Approximately 363,000 Courses of Oral TPOXX\u00ae Delivered to U.S. Government in 2020 \u2013<\/strong>
\n \n <\/p>\n

\n – <\/strong>
\n International Contracts for the Purchase of up to Approximately $47 Million of Oral TPOXX\u00ae Since April 2020 <\/strong>
\n \u2013 <\/strong>\n <\/p>\n

\n – <\/strong>
\n Corporate Update Conference Call Today at 4:30 PM ET <\/strong>
\n –<\/strong>\n <\/p>\n

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2020.<\/p>\n

\u201cSIGA\u2019s fourth quarter and annual financial results are highlighted by the delivery of approximately 112,000 and 363,000 courses, respectively, of oral TPOXX\u00ae to the U.S. strategic national stockpile (SNS), generating revenue from these deliveries of approximately $35 million and $113 million, respectively,\u201d said Phil Gomez, CEO of SIGA. \u201cAdditionally, 2020 marked the announcement of the first international contract for oral TPOXX\u00ae with the contract award by the Canadian Military for its procurement, which was followed by an oral TPOXX\u00ae procurement award in January 2021 by the Public Health Agency of Canada. These combine, including options, to additional cumulative potential revenues of up to approximately $45 million of oral TPOXX\u00ae over the next five years ($2 million of oral TPOXX\u00ae was delivered to the Canadian Military in 2020). We look forward to further expansion in the international procurement of oral TPOXX\u00ae in the coming years.\u201d<\/p>\n

\n
\n Summary Financial Results
($ in millions, except per share amounts)<\/em>
\n <\/strong>\u00a0<\/p>\n

\n
\n Three Months Ended December 31, 2020 in comparison to Three Months Ended
December 31, 2019<\/em>
\n <\/strong>\n <\/p>\n\n\n\n
\u00a0<\/td>\n\n
\n
Three Months
\u00a0Ended
December 31, 2020<\/u><\/strong>\n <\/td>\n		\u00a0<\/td>\n\n
\n
Three Months
Ended
December 31, 2019<\/u><\/strong>\n <\/td>\n<\/tr>\n
Total Revenues
Operating Income (Loss) (1)
Income (Loss) before Income Taxes (1)
Net Income (Loss)
Diluted Income (Loss) per Share<\/td>\n		$37.8
$26.8
$26.2
$20.1
$0.26<\/td>\n		\u00a0<\/td>\n$4.2
($3.4)
($6.5)
($4.5)
($0.06)<\/td>\n<\/tr>\n<\/table>\n

\n
\n Fiscal Year Ended December 31, 2020 in comparison to Fiscal Year Ended December 31, 2019<\/em>
\n <\/strong>\n <\/p>\n\n\n\n
\u00a0<\/td>\n\n
\n
Year
\u00a0Ended
December 31, 2020<\/u><\/strong>\n <\/td>\n		\u00a0<\/td>\n\n
\n
Year
Ended
December 31, 2019<\/u><\/strong>\n <\/td>\n<\/tr>\n
Total Revenues
Operating Income (Loss) (1)
Income (Loss) before Income Taxes (1)
Net Income (Loss)
Diluted Income (Loss) per Share<\/td>\n		$125.0
$84.5
$73.5
$56.3
$0.71<\/td>\n		\u00a0<\/td>\n$26.7
($2.3)
($10.2)
($7.2)
($0.15)<\/td>\n<\/tr>\n<\/table>\n

(1) Operating Income excludes, and Income (Loss) before Income Taxes includes, costs in connection with the retirement of the Company\u2019s term loan, interest expense, interest income and adjustments to the fair value of the Company\u2019s outstanding warrant. Both line items exclude the impact of income taxes.\u00a0<\/p>\n

\n
\n Recent Key Activities:<\/em>
\n <\/strong>\n <\/p>\n